BioSpace News Archive

IQVIA recognized in IDC MarketScape™ for its data and analytics capabilities and growing suite of software platforms.

Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET.

Excess fat accumulation in the liver is detrimental to health and can lead to liver cancer. Given the link between this condition and alcohol consumption, the presence of fatty livers in individuals who don’t consume large amounts of alcohol was termed “non-alcoholic fatty liver disease” or NAFLD in the 1980s.

Notable Labs, Inc., a clinical-stage predictive precision therapeutics company and CicloMed LLC, a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia under the terms of a co-development agreement.

Progress Builds Strong Foundation for Bold 2030+ ESG Goals to Advance the World of Health for All.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VAXNEUVANCE.

Curie Therapeutics Inc today announced a Series A investment of $75 million by its founding syndicate to continue the development of its multimodal pipeline of precision radiopharmaceuticals to a broad range of high unmet need solid tumors.

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total.